The company expects the process of activation, recruitment, enrolling and first dosing to take nearly 3 weeks.
Cellceutix president and chief scientific officer Krishna Menon said institutions such as Dana-Farber and Beth Israel Deaconess are meticulous in their protocol.
”It is this level of excellence that compelled us to sponsor the trials at these clinical sites," Menon added.
Cellceutix chief executive officer Leo Ehrlich said many people have met Menon and him to discuss about Kevetrin and the rest of the Cellceutix pipeline.
”Our novel cancer drug candidate is garnering quite a lot of attention and we are confident that interest is going to continue to grow as the clinical trials progress," Ehrlich added.